Ovarian Cancer
Advertisement
A study that examined whether the combination of AI and knowledge can identify more patients with lung and ovarian cancers.
A study examined whether AI and clinical knowledge can identify more patients with lung and ovarian cancers.
Ovarian cancer patients value personalized follow-up care and reassurance.
Dr. David Gershenson discusses results from the first-ever low-grade serious ovarian cancer impact survey.
A large-scale UK trial of ovarian cancer screening was unable to reduce deaths from the disease, according to a study ...
A study recently found that a conventional carboplatin–paclitaxel doublet regimen was more effective than single-agent ...
Rachel N. Grisham, MD, Section Head, Ovarian Cancer and Director, Gynecologic Medical Oncology at Memorial Sloan ...
According to a new study, population-wide screening for genetic variants linked to hereditary breast and ovarian cancer ...
Women receiving fertility-sparing surgery (FFS) for borderline ovarian tumors were still able to conceive, according to ...
A two-stage surgical approach for cancer prevention is highly acceptable among postmenopausal women at high risk of ...
A randomized phase 2 trial compared outcomes for patients with persistent or recurrent epithelial ovarian cancer (EOC) ...
The low dose use of 2-deoxy-D-gluclose can overcome chemotherapy resistance in an ovarian cancer subtype, according to ...
Women who breastfeed may be reducing their risk for ovarian cancer—including the most deadly type of ovarian cancer, ...
A simple blood test can now measure the body’s own immune response to enhance ovarian cancer diagnosis, according to ...
The findings of a recent JAMA Network Open study indicate that overall survival (OS) is the preferred end point in ...
A large study published in JAMA found no statistically significant association between use of talc powder in the ...
A randomized trial analyzed the efficacy of veliparib as an add-on to first-line induction chemotherapy with carboplatin ...
A new randomized trial evaluated the efficacy of olaparib plus bevacizumab on progression-free survival in women with ...
Secondary surgical cytoreduction followed by chemotherapy does not extend overall survival (OS; primary endpoint) ...
The U.S. Food and Drug Administration (FDA) expanded the approval of Zejula® (niraparib) for advanced ovarian, ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.